Press Release: Cardiomap™
Mapmygenome Launches Cardiomap™ Genetics Test To Predict Heart Disease and Diabetes
Hyderabad, India, September 29, 2013: Mapmygenome announced the launch of Cardiomap™, a genetics-based cardiac health profile, on the World Heart Day, September 29, 2013. This test reports the genetic predisposition to heart diseases, diabetes, and associated risk factors along with the best-fit risk mitigation options such as drug responses and lifestyle changes. When taken with genetic counselling, this test offers the best possible plan for an individual to prevent or manage heart diseases, diabetes, and many other traits such as cholesterol, obesity, and hypertension. Ms. Anu Acharya, CEO of Mapmygenome, said, “Considering the increasing numbers of cases with cardiovascular diseases and diabetes, we felt that an affordable predictive test was the need of the hour. Cardiomap™ is the route map to fight diabetes, heart disease, and many other lifestyle conditions.” Cardiomap™ is Mapmygenome’s second genetics test. Following the success of Genomepatri™, many healthcare institutions have expressed interest in a genetic test for heart disease and diabetes.Cardiomap™ is expected to target a bigger market share considering its affordability.
Cardiomap™ is genetic test for cardiac health profile developed and offered by Mapmygenome. Apart from many heart diseases and metabolic disorders, this test also considers genetic predisposition to several associated conditions such as lipid levels, blood pressure, traits such as QT interval, and lifestyle factors such as alcohol and nicotine dependence and obesity. The risk management section features nutrition and fitness as well as key drug responses. Mapmygenome also offers options for genetic counselling, nutrition counselling, and sourcing of medical expertise. Cardiomap™ enables prevention of heart disease and diabetes by managing the risk for associated conditions; early detection in consultation with medical experts; and selection of best fit treatment from analysis of individual drug responses.
For more information, visit: Cardiomap
Mapmygenome is India’s pioneering personal genomics company with a vision to provide “Better Health for Indians using technology.” They have a range of genetic tests and diagnostic products that include Genomepatri™ for personal genetic profile and Cardiomap™ genetic test for heart disease, diabetes, and other associated lifestyle conditions. These products assess not only genetic risks for diseases, traits, and conditions, but also responses to several drugs prescribed for treatment. Along with their partners, Mapmygenome paves way for customers to receive the best medical attention required to mitigate the risk of diseases.
Mapmygenome also offers brain wellness solutions in India under the portfolio Mapmybrain™. This includes MyCalmBeat™ to reduce stress, to improve lung function, and to optimize heartbeat. Another innovative product in this range is WebNeuro™ test to screen cognitive strengths and efficiency. Their team at Hyderabad comprises biotechnologists, statisticians, geneticists, bioinformaticians, and genetic counsellors. Their advisory panel has expert scientists and doctors. In order to enhance this innovative brand and to provide value-added services to customers, their highly-skilled research team works on cutting-edge technologies in various domains.
For more information, visit: www.mapmygenome.in